Human medicines European public assessment report (EPAR): Ranluspec, ranibizumab, Date of authorisation: 10/02/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised

ETF recommends updating COVID-19 vaccines to target XFG variant

EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027

Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline

List of centrally authorised products with safety-related changes to the product information

Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking

Quality of medicines: questions and answers - Part 2

Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised